SCHEMBL9997373

SCHEMBL9997373

O=C(O)c1ccc(NS(=O)(=O)c2cc(-c3ccc4c(c3)CCO4)cs2)cc1O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 4/20 0.51
PLA2G10 O15496 1/20 0.46
FABP4 P15090 4/20 0.43
PKM P14618 2/20 0.42
PKLR P30613 1/20 0.41
HSD17B10 Q99714 2/20 0.41
ALDH1A1 P00352 1/20 0.41
FABP3 P05413 2/20 0.41
FABP5 Q01469 2/20 0.41
MAPT P10636 1/20 0.41
ERN1 O75460 1/20 0.40
ACLY P53396 1/20 0.40
HPGD P15428 1/20 0.40
MCL1 Q07820 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9997126 0.85 PFKFB3 (0.54) PFKFB3PLA2G10FABP4PKMPKLR
SCHEMBL9997077 0.83 PTGES2 (0.58) PFKFB3FABP4PKMPKLRHSD17B10
SCHEMBL9997131 0.83 PFKFB3 (0.76) PFKFB3FABP4PKMHSD17B10FABP3
SCHEMBL30268499 0.83 PFKFB3 (0.76) PFKFB3FABP4PKMHSD17B10FABP3
SCHEMBL9997308 0.79 ACLY (0.55) PFKFB3PKMHSD17B10ALDH1A1ACLY
SCHEMBL9997230 0.79 ACLY (0.45) PFKFB3PLA2G10FABP4PKMPKLR
SCHEMBL9997181 0.78 PKM (0.44) PFKFB3FABP4PKMPKLRFABP3
SCHEMBL9997365 0.77 ACLY (0.45) PFKFB3FABP4PKMFABP3FABP5
SCHEMBL19281316 0.76 PFKFB3 (0.50) PFKFB3FABP4PKMPKLRHSD17B10
SCHEMBL15055690 0.75 PKLR (0.44) PFKFB3PKMPKLRHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 US disclosed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 CN disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 PFKFB3 1/4885PLA2G10 4072/4885FABP4 871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.